Učitavanje...
TP53 Mutations Promote Immunogenic Activity in Breast Cancer
BACKGROUND: Although immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no immunotherapeutic strategy for breast cancer (BC). Thus, it is important to discover biomarkers for identifying BC patients responsive to immunotherapy. TP53 mutations were often...
Spremljeno u:
| Izdano u: | J Oncol |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Hindawi
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6582869/ https://ncbi.nlm.nih.gov/pubmed/31275382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/5952836 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|